Document is current

Any future updates will be listed below

RPC4046, A Novel Anti-interleukin-13 Antibody, Blocks IL-13 Binding to IL-13 α1 and α2 Receptors: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation First-in-Human Study

Crossref DOI link: https://doi.org/10.1007/s12325-017-0525-8

Published Online: 2017-04-28

Published Print: 2017-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark